Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1256 • ACR Convergence 2024
Higher Disease Activity in Pediatric Systemic Lupus Erythematosus Is Associated with a Greater Desire for Social Health Education: An Unmet Need in Pediatric Rheumatology
Kaitlin Kirkpatrick, Melodee Liegl, Ke Yan and Sara Sabbagh, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: There is limited evidence on the educational needs and preferences of caregivers and adolescents and young adults (AYA) with rheumatic disease (RD) regarding the…
Abstract Number: 1282 • ACR Convergence 2024
Investigating the Genetics of Depression and Anxiety in Children and Adolescents with and Without Systemic Lupus Erythematosus
Indrani Das¹, Nicholas Gold², Christie Burton¹, Jennifer Crosbie¹, JingJing Cao¹, Daniela Dominguez¹, Sefi Kronenberg³, Lawrence Ng², Alene Toulany¹, Hiu-Ki Rachel Tran¹, Gwyneth Zai⁴, Andrea Knight⁵ and Linda Hiraki², ¹The Hospital for Sick Children, Toronto, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Holland-Bloorview Kids Rehabilitation Hospital., Toronto, Canada, ⁴Centre for Addiction and Mental Health, Toronto, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) have a higher prevalence of depression and anxiety compared to healthy peers. Patients with cSLE also have…
Abstract Number: 1496 • ACR Convergence 2024
Dysregulated Serum Cytokines in Association with Clinical Manifestations in Patients with Systemic Lupus Erythematosus
Loqmane seridi¹, Steven Leonardo², Brittney Scott³, Robert Gordon¹, cathye shu¹, Kaiyin Fei¹, Kim Lo³, Anne Stevens¹ and Sheng Gao³, ¹Janssen Research & Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA, ³Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA
Background/Purpose: SLE is a heterogeneous autoimmune disease affecting multiple organ systems, making clinical trial design challenging. Biomarkers that can identify patients with specific clinical manifestations…
Abstract Number: 1512 • ACR Convergence 2024
Association Between the Systemic Immune Inflammatory Index (Sll) and All-cause Mortality in Critically Ill Patients with Rheumatoid Arthritis
Yunfeng Dai and Zhihan Chen, Fujian Medical University, Fuzhou City, Fujian, China (People's Republic)
Background/Purpose: The systemic immune-inflammation index (SII) has been linked to inflammatory and immune responses, with research indicating its impact on rheumatoid arthritis (RA). However, its…
Abstract Number: 1529 • ACR Convergence 2024
Systemic Lupus Erythematous and Neuromyelitis Optica Overlap and Risk of Infection in Hospitalized Patients
Elizabeth Fagin¹, Wei Chapman², fares Saliba³ and Eugenio Capitle⁴, ¹Staten Island University Hospital, Teaneck, ²Staten Island University Hospital, Staten Island, ³Staten Island University Hospital, Staten Island, NY, ⁴University Hospital, Newark
Background/Purpose: Neuromyelitis optica (NMO) is an autoimmune inflammatory disorder that can coexist with systemic lupus erythematous (SLE). Given the immunosuppressive nature of SLE, it is…
Abstract Number: 1549 • ACR Convergence 2024
Prescribing Trends for Novel Treatments in Systemic Lupus from 2017 to 2022
Celestine He¹, Zhonghan Li¹, Sumanth Chennareddy² and Chrisanna Dobrowolski³, ¹Icahn School of Medicine, Mount Sinai, New York, NY, ²Icahn School of Medicine, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Treatment of Systemic Lupus Erythematosus (SLE) has evolved substantially in the past decade. In 2011, the FDA approved belimumab, the first targeted monoclonal antibody…
Abstract Number: 1688 • ACR Convergence 2024
Discovery and Validation of a New Classification of ANA-RMDs That Better Predict Long Term Outcomes Compared to Legacy Diagnoses
Jack Arnold¹, Lucy Carter¹, Yuzaiful Yusof², Zoe Wigston², Daniel Toro Dominguez³, Samuel Relton⁴, Guillermo Barturen⁵, Marta Alarcon-Riquelme⁶ and Edward Vital⁷, and PRECISESADS consortium, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, England, United Kingdom, ³Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica (GENYO), Granada, Andalucia, Spain, ⁴Leeds Institute of Data Analytics, University of Leeds, Leeds, UK, Leeds, England, United Kingdom, ⁵Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ⁶Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom
Background/Purpose: ANA-associated RMDs (ANA-RMDs) include SLE, Sjogren’s, Scleroderma, Myositis, and mixed/undifferentiated CTD. Despite overlapping clinical and immunophenotypic features, there is significant disparity in access to…
Abstract Number: 1780 • ACR Convergence 2024
Next Generation Sequencing Analysis Reveals Complex Genetic Architecture of Childhood-onset Systemic Lupus Erythematosus
Laura Lewandowski¹, Linda Hiraki², Christiaan Scott³, Ana Barrera-Vargas⁴, Diana Gómez-Martin⁵, Michael Ombrello⁶, Ivona Aksentijevich⁷, Zuoming deng⁸, Anthony Musolf⁹, Subrata Paul¹⁰, Dan Hupalo¹¹, Clifton Dalgard¹¹, Sarfaraz Hasni¹², Earl Silverman¹³ and Mariana Kaplan¹⁴, ¹NIAMS, NIH, Bethesda, MD, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Pediatric Rheumatology, Children’s Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Federal District, Mexico, ⁵INCMNSZ, Mexico, Distrito Federal, Mexico, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD, ⁷National Human Genome Research Institute, NIH, Bethesda, MD, ⁸National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁹Computational and Statistical Genomics Branch, NHGRI, NIH, Baltimore, MD, ¹⁰Collaborative Bioinformatics Resource, NIAID, NIH, Bethesda, MD, ¹¹The American Genome Center, Department of Anatomy, Physiology & Genetics, Uniformed Services University, Bethesda, MD, ¹²National Institutes of Health, Bethesda, MD, ¹³Silverman, Toronto, ON, Canada, ¹⁴NIAMS/NIH, Bethesda, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a potentially life-threatening autoimmune disease. Childhood-onset SLE (cSLE) patients have younger disease onset and more severe disease than adults,…
Abstract Number: 1800 • ACR Convergence 2024
WWC1 Regulates Type I Interferon Production Through Modulation of cGAS-STING Signaling in Keratinocytes
Bin Xu, Laura Cencer, Benjamin Klein, Shannon Loftus, Lam Tsoi, Johann Gudjonsson and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Our recent study uncovered a role for dysregulation of the Hippo signaling pathway in systemic lupus erythematosus (SLE) keratinocytes (KCs) driven by overexpression of…
Abstract Number: 1893 • ACR Convergence 2024
Hydroxychloroquine Use in Early Pregnancy and Risk of Preterm Delivery in a Californian Cohort of Lupus Pregnancy
Amadeia Rector¹, Emily Liu², Miranda Cantu³, Eliza Chakravarty⁴, Maurice Druzin⁵, Gary Shaw⁶, Michael Weisman⁷, Monique Hedderson² and Julia Simard⁸, ¹Stanford University, San Francisco, CA, ²Kaiser Permanente Division of Research, Oakland, CA, ³Patient partner, Portage, MI, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Stanford University School of Medicine, Stanford, CA, ⁶Stanford University School of Medicine, Stanford, ⁷Stanford University, Los Angeles, CA, ⁸Stanford School of Medicine, Stanford, CA
Background/Purpose: Preterm delivery (PTD) occurs 2-3 times more frequently in patients with systemic lupus erythematosus (SLE) compared to the general obstetric population. Hydroxychloroquine (HCQ), a…
Abstract Number: 2183 • ACR Convergence 2024
Accuracy of AI Tools for Diagnosis of Connective Tissue Disease
Indira Sriram¹, Gabriel Tarshish² and Megan Curran², ¹University of Colorado, Aurora, CO, ²Children's Hospital Colorado, Aurora, CO
Background/Purpose: In this work, we study the ability of generative artificial intelligence (AI) based tools to diagnose pediatric rheumatological diseases. Specifically, we seek to answer…
Abstract Number: 2384 • ACR Convergence 2024
Performance and Concordance of Two Different Methods of Detecting the Commonest Autoantibodies in Systemic Lupus Erythematosus
Ranjan Gupta¹, Sonam Rajput², Rudra Prosad Goswami², Jayanth Kumar² and Amita Aggarwal³, ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²All India Institute of Medical Sciences, New Delhi, New Delhi, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Autoantibodies in SLE can be detected by either immunoblot assay or by ELISA. Both these methods may have variable performance with respect to the…
Abstract Number: 2403 • ACR Convergence 2024
Health-related Quality of Life in Women with Systemic Lupus Erythematosus with Permanent Skin Damage and Its Association with Self-esteem and Symptoms of Depression and Anxiety – a Cross-sectional Study
Fernando A Oliveira¹, Fabiana Moura², Ana Flávia Dias³, Claudia Santoro³, Fernando Pereira², Rosa Telles² and Cristina Lanna², ¹Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, ²Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, ³Grupo Santa Casa de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil
Background/Purpose: Body image of systemic lupus erythematosus (SLE) patients is affected by the mucocutaneous manifestations and its scars, in particular related to discoid lupus. The…
Abstract Number: 2420 • ACR Convergence 2024
Blood Transcriptome Analysis Reveals Enhanced B Cell and Complement Cascade Signatures in Patients with Major Neuropsychiatric Systemic Lupus Erythematosus
Dionysis Nikolopoulos¹, George Sentis², Jason Kitsos², Panagiotis Garantziotis³, Noemin Kapsala², antigoni Pieta², Myrto Nikoloudaki⁴, Theodora Manolakou⁵, Sofia Flouda², Ioannis Parodis⁶, Anastasia Filia², George Bertsias⁷, Antonis Fanouriakis² and Dimitrios Boumpas⁸, ¹Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ²National and Kapodistrian University of Athens, Athens, Greece, ³Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, ⁴Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece, Heraklion, Greece, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ⁷Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology, Heraklion, Greece, ⁸4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece, Athens, Greece
Background/Purpose: The molecular basis of neuropsychiatric systemic lupus erythematosus (NPSLE) remains elusive because of clinical heterogenicity, the complexity of pathophysiologic mechanisms involved and limited access…
Abstract Number: 2437 • ACR Convergence 2024
Aryl Hydrocarbon Receptor as an Intrinsic Novel Checkpoint That Inhibits TLR7-induced B-cell Activation in SLE
Changming Lu¹, Jose Rubio², Hui-Chen Hsu¹ and John D. Mountz³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Hoover, AL, ³University Alabama Birmingham, Birmingham, AL
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by an increase in T-bet+ IgD−CD27− double negative 2 (DN2) B cells, attributed to heightened TLR7 signaling. Identifying…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].